

The Role of MicroRNA-21 and Autophagy in Liver Fibrosis

Rituraj Niranjan^{1*}, Ritambhara², Kaushal Prasad Mishra¹, Sivakumar Vijayaraghavalu³, Amit Goel⁴ and Munish Kumar^{2,5}

¹Department of Biological Sciences and Bioengineering (BSBE), Indian Institute of Technology, Kanpur, Uttar Pradesh, India

²Department of Biochemistry, University of Allahabad, Allahabad, Uttar Pradesh, India

³Cleveland Lerner College of Medicine, Case western Reserve University, Cancer Nanomedicine Program, Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA

⁴Department of Gastroenterology, C-Block, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

⁵Department of Cancer Biology, Cleveland Clinic, Cleveland, Ohio, USA

*Corresponding author: Rituraj Niranjan, Department of Biological Sciences and Bioengineering (BSBE), Indian Institute of Technology, Kanpur, Uttar Pradesh, India, Tel: 501-707-8928; E-mail: riturajniranjan@rediffmail.com

Received date: June 30, 2017; Accepted date: July 18, 2017; Published date: July 20, 2017

Copyright: © 2017 Niranjan R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Mini Review

Liver fibrosis is a multifactorial disorder arises primarily due to excessive accumulation of scar and dead tissues that cannot be bio transformed by the liver cells. Fibrosis occurs because of vascular remodelling and several factors are involved in the process [1]. In most of the chronic liver diseases and liver fibrosis, there is significant increase in inflammation and stress followed by vascular remodelling because of extra cellular matrix deposition [2]. Liver injury occurs because of several factors among them the prominent are hepatitis B or hepatitis C virus infections, stress, xenobiotics, alcohol consumption, non-alcoholic steatohepatitis (NASH) [3]. The liver enzymes are unable to degrade scar tissue and the response goes inappropriate and resulting in deposition of more collagen and degradation of elastin in the development of fibrosis [4].

Autophagy is evolutionarily conserved physiological process involved in maintaining the normal functioning of the cells by engulfing the self-organelles and cytoplasmic contents in conditions of nutritional demands [5]. It is initiated during stress and provides an alternate mechanism of intracellular substrate availability for synthesis of larger molecules [6]. Autophagy is involved in tissue remodelling during embryonic development [7]. Involvement of autophagy in the liver fibrosis and other liver diseases is a well-established fact [4,8,9]. However, there is no direct link for miRNA-21 involvement in development of liver fibrosis [10,11]. It's possible that it could play an important role in etiology of the disease by modulating autophagy.

In recent years MicroRNAs (miRNAs) has evolved as one of the major players in understanding the development of human diseases including liver disease. miRNAs are small (21-25 nucleotide) non-coding RNAs that are considered as unique paradigm shifters due to their involvement in most of the physiological processes by regulation of gene at post transcriptional level [12-14]. Studies documented the increased expression of miRNAs such as miR-21 and miR-199 in hepatitis and liver cancer. miR-21 has been shown to promote fibro genesis in muscles and various organs including heart, kidneys, lungs and liver [15]. In liver it induces fibrosis by activating hepatic stellate cells (HSC) [16]. Recently, Ning Zuo-Wei et al. (2017) showed that over expression of mir-21 promotes oxidation, increases in collagen production and to have profound effect on angiotensin activation via Spry1/ERK/NF-κB, Smad7/Smad2/3/NOX4 pathways and its down regulation exerted the opposite effects [16,17]. Our article in PNAS, showed the miR-21 KO mice have reduced tumorigenic activity in multistage murine skin carcinogenesis model [18], indicating down regulation of miRNA could have therapeutic role in cancer therapy

[18]. Also another recent study demonstrated the ablation of miR-21 resulted in progressive decrease in steatosis, inflammation and lipoapoptosis with impairment of fibrosis [19]. Similarly, in a different study Kennedy et al. showed the loss of miR-21 expression resulted in decreased collagen deposition and expression of fibrotic markers transforming growth factor-β1 and α-smooth muscle actin in mice model [20]. Further, he demonstrated that human HSCs treated with miR-21 inhibitor in vitro significantly decreased the cell proliferation and expression of fibrotic markers and enhanced the cell apoptosis [20]. The same study linked the increased in Smad-7 expression, decreased biliary hyperplasia and hepatic fibrosis in knocking down miR-21 expression [20].

We conclude that, miR-21 along with autophagy plays major role in liver vascular remodelling and has prominent role in increasing hepatic fibrosis. Thus we propose that modulating miR-21 and autophagy may be a therapeutic option for patients with liver disease and many other diseases in near future.

Acknowledgement

The “young scientist fellowships grant No: SB/YS/LS-198/2014 “(Institutional project No. SERB/BSBE/2016-271)” to Dr. Rituraj Niranjan by SERB (DST, India.) is gratefully acknowledged.

References

1. Sun K, Xu L, Jing Y, Han Z, Chen X, et al. (2017) Autophagy-deficient Kupffer cells promote tumorigenesis by enhancing mtROS-NF-kappaB-IL1alpha/beta-dependent inflammation and fibrosis during the preneoplastic stage of hepatocarcinogenesis. *Cancer Letters* 388: 198-207.
2. Gual P, Gilgenkrantz H, Lotersztajn S (2017) Autophagy in chronic liver diseases: the two faces of Janus. *American J physiol Cell physiol* 312: C263-C273.
3. Mao YQ, Fan XM (2015) Autophagy: A new therapeutic target for liver fibrosis. *World J hepatol* 7: 1982-1986.
4. Zhang J, Ping J, Xu L (2014) The role of autophagy in hepatic fibrosis. *Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi. Chinese J Hepatol* 22: 708-710.
5. Chen S, Rehman SK, Zhang W, Wen A, Yao L, et al. (2010) Autophagy is a therapeutic target in anticancer drug resistance. *Biochim Biophys Acta* 1806: 220-229.
6. Chen S, Yuan J, Yao S, Jin Y, Chen G, et al. (2015) Lipopolysaccharides may aggravate apoptosis through accumulation of autophagosomes in alveolar macrophages of human silicosis. *Autophagy* 11: 2346-57.

7. Mizumura K, Cloonan S, Choi ME, Hashimoto S, Nakahira K, et al. (2016) Autophagy: Friend or Foe in Lung Disease? *Ann Am Thoracic Soc* 13: S40-S47.
8. Nho RS, Hergert P (2014) FoxO3a and disease progression. *World J Biol Chem* 5: 346-354.
9. Xu JY, Li ZP, Zhang L, Ji G (2014) Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. *World J Gastroenterol* 20: 13493-13500.
10. Xu X, Fu Y, Tong J, Fan S, Xu K, et al. (2014) MicroRNA-216b/Beclin 1 axis regulates autophagy and apoptosis in human Tenon's capsule fibroblasts upon hydroxycamptothecin exposure. *Exp Eye Res* 123: 43-55.
11. Gozuacik D, Akkoc Y, Ozturk DG, Kocak M (2017) Autophagy-Regulating microRNAs and Cancer. *Frontiers in oncology* 7: 65.
12. Mishra PJ, Merlino G (2009) MicroRNA reexpression as differentiation therapy in cancer. *J clinical investigation* 119: 2119-2123.
13. Mishra PK, Tyagi N, Kundu S, Tyagi SC (2009) MicroRNAs are involved in homocysteine-induced cardiac remodeling. *Cell Biochem Biophys* 55: 153-162.
14. Huang W (2017) MicroRNAs: Biomarkers, Diagnostics, and Therapeutics. *Methods Mol Biol* 1617: 57-67.
15. Mishra PJ, Bertino JR (2009) MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. *Pharmacogenomics* 10: 399-416.
16. Ning ZW, Luo XY, Wang GZ, Li Y, Pan MX, et al. (2017) MicroRNA-21 Mediates Angiotensin II-Induced Liver Fibrosis by Activating NLRP3 Inflammasome/IL-1beta Axis via Targeting Smad7 and Spry1. *Antioxid Redox Signal* 27: 1-20.
17. Tu H, Sun H, Lin Y, Ding J, Nan K, et al. (2014) Oxidative stress upregulates PDCD4 expression in patients with gastric cancer via miR-21. *Curr Pharm Des* 20: 1917-23.
18. Ma X, Kumar M, Choudhury SN, Becker Buscaglia LE, Barker JR, et al. (2011) Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. *Proc Natl Acad Sci USA* 108: 10144-10149.
19. Rodrigues PM, Afonso MB, Simao AL, Carvalho CC, Trindade A, et al. (2017) miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. *Cell Death Dis* 8: e2825.
20. Kennedy LL, Meng F, Venter JK, Zhou T, Karstens WA, et al. (2016) Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. *Lab Invest* 96: 1256-1267.